Page 66 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 66
THURSDAY, APRIL 23, 2015
Parallel Session: Viral Hepatitis C: Therapy (Cont.) Hall D
ABSTRACT C-SWIFT: GRAZOPREVIR/ELBASVIR + SOFOSBUVIR IN
O006 CIRRHOTIC AND NONCIRRHOTIC, TREATMENT-NAIVE
17:15 - 17:30 PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1
INFECTION, FOR DURATIONS OF 4, 6 OR 8 WEEKS AND
SCIENTIFIC PROGRAMME GENOTYPE 3 INFECTION FOR DURATIONS OF 8 OR 12
WEEKS
Fred Poordad, The United States
ABSTRACT ALL ORAL HCV THERAPY IS SAFE AND EFFECTIVE
O007 IN PATIENTS WITH DECOMPENSATED CIRRHOSIS:
17:30 - 17:45 INTERIM REPORT FROM THE HCV-TARGET REAL
WORLD EXPERIENCE
Rajender Reddy, The United States
ABSTRACT EFFICACY AND SAFETY OF GRAZOPREVIR AND
O008 ELBASVIR IN HEPATITIS C GENOTYPE 1–INFECTED
17:45 - 18:00 PATIENTS WITH CHILD-PUGH CLASS B CIRRHOSIS
(C-SALT PART A)
Ira M. Jacobson, The United States
Parallel Session: General Viral Hepatitis Hall C (Plenary)
Chairs:
Massimo Levrero, Italy
Daniel Shouval, Israel
ABSTRACT A PROSPECTIVE STUDY OF HEPATITIS B REACTIVATION
O009 IN PATIENTS WITH PRIOR HBV EXPOSURE
16:00 - 16:15 UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION: REACTIVATION ASSOCIATION
ABSTRACT WITH GRAFT-VERSUS-HOST DISEASE
O010 Wai-Kay Seto, Honduras
16:15 - 16:30
T AND B CELL RESPONSES AND PREVIOUS EXPOSURE
TO HEPATITIS B VIRUS IN “ANTI-HBC ALONE” PATIENTS
Nasser Semmo, Germany
66 The International Liver Congress™ 2015 • ILC Programme
Parallel Session: Viral Hepatitis C: Therapy (Cont.) Hall D
ABSTRACT C-SWIFT: GRAZOPREVIR/ELBASVIR + SOFOSBUVIR IN
O006 CIRRHOTIC AND NONCIRRHOTIC, TREATMENT-NAIVE
17:15 - 17:30 PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1
INFECTION, FOR DURATIONS OF 4, 6 OR 8 WEEKS AND
SCIENTIFIC PROGRAMME GENOTYPE 3 INFECTION FOR DURATIONS OF 8 OR 12
WEEKS
Fred Poordad, The United States
ABSTRACT ALL ORAL HCV THERAPY IS SAFE AND EFFECTIVE
O007 IN PATIENTS WITH DECOMPENSATED CIRRHOSIS:
17:30 - 17:45 INTERIM REPORT FROM THE HCV-TARGET REAL
WORLD EXPERIENCE
Rajender Reddy, The United States
ABSTRACT EFFICACY AND SAFETY OF GRAZOPREVIR AND
O008 ELBASVIR IN HEPATITIS C GENOTYPE 1–INFECTED
17:45 - 18:00 PATIENTS WITH CHILD-PUGH CLASS B CIRRHOSIS
(C-SALT PART A)
Ira M. Jacobson, The United States
Parallel Session: General Viral Hepatitis Hall C (Plenary)
Chairs:
Massimo Levrero, Italy
Daniel Shouval, Israel
ABSTRACT A PROSPECTIVE STUDY OF HEPATITIS B REACTIVATION
O009 IN PATIENTS WITH PRIOR HBV EXPOSURE
16:00 - 16:15 UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION: REACTIVATION ASSOCIATION
ABSTRACT WITH GRAFT-VERSUS-HOST DISEASE
O010 Wai-Kay Seto, Honduras
16:15 - 16:30
T AND B CELL RESPONSES AND PREVIOUS EXPOSURE
TO HEPATITIS B VIRUS IN “ANTI-HBC ALONE” PATIENTS
Nasser Semmo, Germany
66 The International Liver Congress™ 2015 • ILC Programme
